Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Utilizzo della realtà virtuale omnidirezionale e dell'allenamento su tapis roulant per l'ictus cronico (PROVE)

2 ottobre 2026 aggiornato da: Adria Quigley, Nova Scotia Health Authority

PROVE-VR: uno studio pilota randomizzato che utilizza la realtà virtuale omnidirezionale e l'addestramento su tapis roulant per sopravvissuti a ictus cronico

The primary objective of this pilot randomized controlled trial (RCT) is to test the feasibility (consent rate, retention rate, participant burden, adherence, technical issues, safety) and usability (system usability scale, SUS) of Omnidirectional treadmill Virtual Reality training (omni-VR) among chronic stroke survivors. Our secondary objective is to (1) estimate the extent to which cognition, brain activation during a dual task activity, walking ability, and dynamic balance change after 3 months of training among intervention participants (omni-VR) and traditional exercise controls, and (2) estimate the extent to which health-related quality of life and motivation co-evolve with our secondary outcomes.

Researchers will compare the intervention group and control group to evaluate the impact of omni-VR on cognition and physical function among stroke survivors.

Participants will:

  • undergo a 45-minute training session 3 times per week for 12 weeks
  • intervention group: omni-VR
  • control group: traditional exercise program (strengthening and walking activities)

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Mounting data indicates that cognition plays a role in complex walking and balance. However, conventional intervention methods lack a sufficient incentive to encourage participants to adhere to the treatment. Further, it is difficult to provide a substantial amount of treatment to induce cortical reorganization.

Virtual reality or VR (a computer-generated simulation of 3-dimensional virtual environments that reacts in real time to the user's actions) has been introduced to neurorehabilitation to promote improvements in walking ability, balance, and cognition. It has also been demonstrated to be effective in improving motivation among stroke survivors and augmenting neuroplasticity.

Omnidirectional treadmill technology can be integrated with VR to allow for fully immersive rehabilitation. This novel and innovative technology mimics real-world environments and maximizes challenging cognitive and physical dual-tasking and balance activities while maintaining patient safety. However, no randomized trials have evaluated the impact of omnidirectional treadmill VR (Omni-VR) on cognitive and physical function among stroke survivors.

Therefore, our study aims to test the feasibility and usability of the Omni-VR. This pilot randomized control trial will also be the first study to test the feasibility and effect of a fully-immersive active omni-VR system among chronic stroke survivors

Tipo di studio

Interventistico

Iscrizione (Stimato)

30

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

  • Canada
    • Nova Scotia
      • Halifax, Nova Scotia, Canada, B3H 4K4
        • Reclutamento
        • Nova Scotia Rehabilitation & Arthritis Centre
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria

  • Age ≥ 18
  • Stroke ≥ 6 months ago (confirmed with chart review)
  • Living within 50 km of Halifax, Nova Scotia
  • Functional Ambulation Category of 3 or greater on a scale of 0-5, to ensure the participant is able to walk with supervision or independently. This criterion was selected to ensure participants could safely participate in the intervention.
  • Ability to participate in low-moderate intensity aerobic or strengthening exercise for ≥ 15 minutes to ensure participants can tolerate intervention sessions of 30-45 minutes, with activity breaks, in keeping with previous stroke rehabilitation studies.
  • No uncorrected visual deficits or spatial neglect
  • No cardiovascular, orthopedic, or neurological diseases other than stroke impacting walking or balance
  • Can follow simple instructions
  • Score of < 27 on the adapted Motion Sickness Susceptibility Scale-Short based on established normative values indicating more than moderate susceptibility to motion sickness.

Exclusion Criteria:

  • Unstable serious medical condition
  • Resting blood pressure >180/100mmHg
  • History of abnormal untreated heart rhythm
  • Pregnancy
  • Condition limiting ability to complete or tolerate the exercises without major program modifications (e.g., chronic low back pain)
  • Serious comorbid condition that would affect participation in the intervention (e.g., active cancer, severe heart disease)
  • Severe loss of hearing or speech that would preclude VR use
  • Participant weight more than 264 lbs (weight limit for Virtualizer Elite 2 treadmill)
  • Participating in another formal lower limb exercise program > 1 day per week
  • History of QT prolongation or using potential QT prolonging drugs

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Omni-VR group

20 participants will undergo 45-minute training sessions 3 times per week for 12 weeks using omnidirectional virtual reality and treadmill training.
Dispositivo: Omnidirectional Virtual Reality and Treadmill Training

Omni-VR forest scenario developed by our team involving real-life dual task walking and dynamic balance activities (ie. stepping over obstacles, and managing distractions) will be used for treatment group.
Comparatore attivo: Control group

10 participants will undergo 45-minute traditional physiotherapy training sessions including lower limb strengthening and unidirectional treadmill training 3 times per week for 12 weeks.
Comportamentale: Traditional Exercise

A traditional exercise program including strengthening and unidirectional treadmill activities for the same duration will be completed in control group.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Consent rate
Lasso di tempo: Baseline

Consent rate is the percentage of eligible individuals who participate. The investigators expect a consent rate of at least 40%.
Baseline
Retention rate
Lasso di tempo: 12 weeks (study completion)

Retention rate is the percentage of participants who complete the 12-week intervention. The investigators expect a retention rate of 80% for the intervention group.
12 weeks (study completion)
Usability of the Omnidirectional Treadmill and Virtual Reality Game
Lasso di tempo: 12 weeks (study completion)

Usability will be assessed by System Usability Scale (SUS) out of 100 points. The investigators expect a SUS score of 71 or higher among all participants.
12 weeks (study completion)
Participant burden
Lasso di tempo: Baseline and 12 weeks (study completion)

Participant burden will be measured by the percentage of participants finishing assessments in 100 minutes or less. The investigators anticipate at least 85% of participants completing assessments within the time limit.
Baseline and 12 weeks (study completion)
Adherence
Lasso di tempo: 12 weeks (study completion)

Adherence will be measured by the exercise session attendance. The investigators expect the treatment group to attend 70% or more of the sessions.
12 weeks (study completion)
Equipment downtime
Lasso di tempo: 12 weeks (study completion)

The investigators will record any treadmill downtime due to VR technical issues. The targets are zero significant downtime in 85% of sessions.
12 weeks (study completion)
Equipment safety
Lasso di tempo: 12 weeks (study completion)

The investigators will record any serious adverse events related to the study. The target is no serious adverse events related to the study
12 weeks (study completion)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Cognitive function
Lasso di tempo: Baseline and 12 weeks (study completion)

The investigators will use the Computerized MoCA [Montreal Cognitive Assessment] Duo to evaluate participants' cognitive function.
Baseline and 12 weeks (study completion)
Executive Function
Lasso di tempo: Baseline and 12 weeks (study completion)

The investigators will use the Dimensional Change Card Sort to evaluate participants' executive function.
Baseline and 12 weeks (study completion)
Working memory
Lasso di tempo: Baseline and 12 weeks (study completion)

The investigators will use the List Sorting Working Memory Test to evaluate participants' working memory.
Baseline and 12 weeks (study completion)
Brain activation in prefrontal and premotor cortices
Lasso di tempo: Baseline and 12 weeks (study completion)

Brain activation using fNIRS [Functional near-infrared spectroscopy] in the prefrontal and premotor regions of interest during a single task (steady-state omnidirectional treadmill walking) and two cognitive-physical dual-task activities (simple dual-task: steady-state omnidirectional treadmill walking while repeating the same word and complex dual-task: steady-state omnidirectional treadmill walking while performing a verbal fluency test)
Baseline and 12 weeks (study completion)
Walking Speed
Lasso di tempo: Baseline and 12 weeks (study completion)

Walking speed using VIVE trackers on omnidirectional treadmill and overground
Baseline and 12 weeks (study completion)
Step cadence
Lasso di tempo: Baseline and 12 weeks (study completion)

The investigators will evaluate step cadence using the VIVE trackers.
Baseline and 12 weeks (study completion)
Step width
Lasso di tempo: Baseline and 12 weeks (study completion)

The investigators will evaluate step width using the VIVE trackers.
Baseline and 12 weeks (study completion)
Step length
Lasso di tempo: Baseline and 12 weeks (study completion)

The investigators will evaluate step length using the VIVE trackers.
Baseline and 12 weeks (study completion)
Dynamic balance
Lasso di tempo: Baseline and 12 weeks (study completion)

The investigators will measure the static sway with feet together using omni-VR system and use MINI-BESTest to measure the dynamic balance.
Baseline and 12 weeks (study completion)

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Motivation of participant
Lasso di tempo: 12 weeks (study completion)

The investigators will measure motivation by intrinsic motivation inventory. Higher scores indicate better results.
12 weeks (study completion)
Health-related quality of life of participant
Lasso di tempo: Baseline and 12 weeks (study completion)

The investigators will measure health-related quality of life by the Stroke Impact Scale-3.0. Higher scores indicate better results.
Baseline and 12 weeks (study completion)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Nova Scotia Health Authority

Collaboratori

Brain Canada

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

28 aprile 2025

Completamento primario (Stimato)

6 agosto 2027

Completamento dello studio (Stimato)

6 settembre 2027

Date di iscrizione allo studio

Primo inviato

20 giugno 2024

Primo inviato che soddisfa i criteri di controllo qualità

3 luglio 2024

Primo Inserito (Effettivo)

10 luglio 2024

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

6 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

2 ottobre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • PROVE_stroke

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi